Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

Abstract Background In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. Methods This open‐label, Phase 1 study enrolled Japanese adult patients to receive E7389‐LF for the treatment of...

Full description

Bibliographic Details
Main Authors: Hibiki Udagawa, Shunji Takahashi, Motohiro Hirao, Makoto Tahara, Satoru Iwasa, Yasuyoshi Sato, Takuya Hamakawa, Kohei Shitara, Hidehito Horinouchi, Keisho Chin, Norikazu Masuda, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai, Kan Yonemori
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cancer Medicine
Subjects:
advanced solid tumors
E7389‐LF
eribulin
granulocyte‐colony stimulating factor
liposome
Online Access:https://doi.org/10.1002/cam4.4996

Internet

https://doi.org/10.1002/cam4.4996

Similar Items